	From Technological Innovation to Clinical Translation: Progress and Challenges in 3D Bioprinting for the Development of Breast Cancer Bone Metastasis Models. Adv Healthc Mater Miao L, Jiang D, Zhang X, Kang Y. PMID: 42216436 [PubMed - as supplied by publisher]
	Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171. Cancer Ballinger TJ, Zhao F, Jiang G, Shen F, Cella D, Peipert JD, Miller KD, Wolff AC, DeMichele AM, Schneider BP, Wagner LI. PMID: 42216434 [PubMed - indexed for MEDLINE]
	False-positive mammogram has a negative impact on quality of life: A cross-sectional study among Jordanian women at King Abdullah University Hospital. Medicine (Baltimore) Gharaibeh MM, Elobeid EA, Ahmmed SM, Fataftah JZ, Khasawneh RA, Rawashdeh MA, El-Heis SM, Gharaibeh SI, Elheis MA. PMID: 42216337 [PubMed - indexed for MEDLINE]
	The causal role of plasma metabolites in breast cancer susceptibility mediated by immune cells: A two-sample Mendelian randomization analysis. Medicine (Baltimore) Sun Z, Ge F, Duan W, Qian J, Chen L. PMID: 42216331 [PubMed - indexed for MEDLINE]
	Bioconjugates for breast cancer theranostics: improving target selectivity and treatment efficacy. Expert Opin Drug Deliv Jain N, Kaul S, Verma R, Sharma A, Pandey M, Chaudhary A, Nagaich U. PMID: 42216243 [PubMed - as supplied by publisher]
	Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study. Breast Cancer Res Ishikawa T, Uemura Y, Seki H, Kitada M, Saito T, Yamada K, Takao S, Takabatake D, Yokota T, Kitahara M, Kikawa Y, Yamada A, Toh U, Nishimura H, Kaise H, Yamagami K, Nishimura R, Taira N, Narui K, Mukai H. PMID: 42216212 [PubMed - as supplied by publisher]
	Atezolizumab versus pembrolizumab in the treatment of advanced triple-negative breast cancer: a Bayesian network meta-analysis of ITT and PD-L1 positive populations. BMC Cancer Wiguna IGWW, Sadeva IGKA, Mamangdean CT, Mahayana NPK, Khanaruksombat S, Thu MS, Putri PMWS, Tungga KMK, Kepakisan ABN, Arta KIP, Pratama RP, Hirankarn N. PMID: 42215937 [PubMed - as supplied by publisher]
	Exercise-related genes predicts overall survival and tumor immune microenvironment, and identifies the biological role of SLC52A2 in breast cancer. Discov Oncol Chen C, Han C, Xue L, Lu X. PMID: 42215809 [PubMed - as supplied by publisher]
	Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial results. NPJ Breast Cancer Bellet M, Ferrero-Cafiero JM, Bergamino Sirvén M, Falato C, González X, Amillano K, Chic N, Morales S, Gasol A, Nuciforo P, Villacampa G, Villagrasa P, Diep CH, Seelig D, Lange C, D'Assoro A, Prat A, Pascual T, Saura C. PMID: 42215464 [PubMed - as supplied by publisher]
	Comment on "The Meaning of Surveillance in Women With a Hereditary Risk of Breast Cancer: A Hermeneutic Phenomenological Study". J Clin Nurs Kumar K V V, Kshirsagar P, Mishra M, Panwar S. PMID: 42215305 [PubMed - as supplied by publisher]
	Contextual interpretation of luminal phenotype in low-grade breast epithelial proliferations. J Clin Pathol Rakha EA. PMID: 42215291 [PubMed - as supplied by publisher]
	Concordance between clinician-reported toxicities and patient-reported symptom severity in early-stage breast cancer: an analysis of the randomized phase III PANTHER trial. ESMO Open Filis P, Liu X, Matikas A, Untch M, Steger GG, Johansson H, Hellström M, Gnant M, Loibl S, Brandberg Y, Bergh J, Foukakis T. PMID: 42215159 [PubMed - indexed for MEDLINE]
	Erector spinae plane block vs. paravertebral block for postoperative analgesia in breast surgery: a meta-analysis of randomized trials. Braz J Anesthesiol Dost B, Karapinar YE, Beldagli M, Turunc E, Kaya C, de Cassai A. PMID: 42214789 [PubMed - as supplied by publisher]
	Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial. Ann Oncol Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, Ribi K, Ruddy KJ, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Partridge AH, International Breast Cancer Study Group, POSITIVE Trial Consortium. PMID: 42214557 [PubMed - as supplied by publisher]
	Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study. Breast Pontolillo L, Munzone E, Vigneri P, Pistelli M, Palazzo A, La Verde N, Mazzotta M, Paris I, Alesini D, Santini D, Cannita K, Orlandi A, Magnolfi E, Giacinti L, Raffaele M, Carbognin L, Santoro A, Rossi A, Arcuri G, Sangalli C, Garrone O, Mulè A, Valenza C, Berardi R, Tortora G, Bria E, Curigliano G, Giannarelli D, Fabi A. PMID: 42214155 [PubMed - as supplied by publisher]
	Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer (ARETTA). JCO Glob Oncol Ntekim A, Popoola A, Sowunmi A, Olasehinde O, Sanni A, Ibraheem A, Zheng Y, Yoshimatsu TF, Dosunmu GT, Omoleye O, Folasire A, Adeniji-Sofoluwe A, Omisore A, Adewumi A, Olajide T, Lawal R, Komolafe A, Omodele F, Ajani M, Michael O, Balogun B, Ale OK, Irurhe N, Folorunso S, Oyekan A, Kotila O, Aniagwu T, Odetunde A, Ilona S, Ajani AO, Oshin A, Onitilo A, Asuzu C, Daramola A, Abdulkareem F, Balogun OO, Karrison T, Babalola P, Huo D, Olopade CO, Obafunwa J, Ojengbede O, Olopade OI. PMID: 42214048 [PubMed - indexed for MEDLINE]
	Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource Settings. JCO Glob Oncol Peres Moreira RJ, Bines J, Dhungana A, Freeman JQ, Saha P, Sullivan ME, Yao K, Flores EM, Huo D, Pearson AT, Small IA, Olopade OI, Howard FM. PMID: 42214047 [PubMed - indexed for MEDLINE]
	Machine learning models based on magnetic resonance imaging for predicting Lymphovascular Invasion in Invasive Breast Cancer. PLoS One Li H, Huang J, Hou J, Chen X, Zhi C, Li Z. PMID: 42213726 [PubMed - indexed for MEDLINE]
	Statins and risk of cardiovascular disease: Emulating a primary prevention trial in breast cancer survivors. J Natl Cancer Inst Russo RG, Hernán MA, Dahabreh IJ, Rimm EB, Veiga LHS, Hurson AN, Curtis RE, Pfeiffer RM, Booker QS, Corley ME, Mitra PR, Ryerson AB, Honda S, White L, Feigelson HS, Aiello Bowles EJ, Roger VL, Ramin C, Barac A, Gierach GL, Danaei G, Vo JB. PMID: 42213587 [PubMed - as supplied by publisher]
	Correction: Differences in drug efficacy and prognosis between primary and metastatic sites for de novo stage IV breast cancer: an exploratory analysis of a phase III trial, JCOG1017. Breast Cancer Tanaka K, Shimomura A, Ishitobi M, Yamanaka T, Tsukioki T, Iwata H, Hara F, Fujisawa T, Sasaki K, Sadachi R, Kajikawa R, Sakai T, Sagara Y, Shigematsu H, Ozaki Y, Nozawa K, Sudo K, Naito Y, Terata K, Ishiba T, Fukuda H, Shien T. PMID: 42213365 [PubMed - as supplied by publisher]

Articles 1 - 20 / 218298

Page 1 of 10915



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy